{"entity":{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","aka":[],"tldr":"Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.","summary":"Angela DeMichele is Co-Leader of the Breast Cancer Research Program and the Alan and Jill Miller Professor in Breast Cancer Excellence at the Abramson Cancer Center, University of Pennsylvania. She is a medical oncologist known for conducting the first palbociclib clinical trial in breast cancer and for co-leading the I-SPY 2 adaptive platform trial. Her selected paper reports the phase 2 activity, safety and predictive biomarkers of the CDK4/6 inhibitor palbociclib in Rb-positive advanced breast cancer. She now studies disseminated tumour cell dormancy as a target for preventing late recurrence in hormone receptor-positive and triple-negative breast cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6"],"drugs":["palbociclib"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Leader, Breast Cancer Research Program; Alan and Jill Miller Professor in Breast Cancer Excellence","institutionId":"penn-abramson","specialisms":["Breast cancer","CDK4/6 inhibitors","I-SPY 2 platform trial","Dormancy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D"}],"papers":[{"title":"CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-14-2258","doi":"10.1158/1078-0432.CCR-14-2258"}],"orcid":"0000-0003-1297-4251"},"route":"/people/angela-demichele/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"}],"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"}]}}